Contraception News and Research

Latest Contraception News and Research

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

The World Health Organization released its 2015 updated essential medicines list and for the first time included the progesterone contraceptive vaginal ring (CVR), a contraceptive safe and effective for lactating women in the postpartum period.

10 Jun 2015

Study compares costs of immediate birth control implant insertion with costs of unintended pregnancy

Women who have just given birth are often motivated to prevent a rapid, repeat pregnancy. For those who prefer a contraceptive implant, getting the procedure in the hospital immediately after giving birth is more cost-effective than delaying insertion to a 6-8 week postpartum visit, according to a new study by Yale School of Medicine researchers.

10 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

New tool kit aims to support family planning efforts

In developing regions where the economy is weak and medical services are limited, global health experts say as many as 200 million women want access to long-term, reversible contraceptives to avoid unintended pregnancies and to help space out the births of their children.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

As more infants are born to mothers with dependence on prescription pain medications, the costs of treatment for babies with neonatal abstinence syndrome (NAS) have increased dramatically, suggests a report in the March/April issue of the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine.

20 May 2015

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Each year, around 55,000 more women than men will have a stroke. Longer lifespans, pregnancies and hormones all contribute to the disparity, as do illnesses that tend to strike women more frequently. Crunch the numbers and the math adds up to more strokes for women, making it important for women monitor their risk.

8 May 2015

Penn study highlights need for more guidance on contraceptive use in women with cystic fibrosis

Only half of women with cystic fibrosis (CF) report using contraception and frequently apt to become pregnant unintentionally, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

7 May 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

5 May 2015

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Is the end of HIV near? Findings published this week in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

29 Apr 2015

National survey shows that most women don't know risks or symptoms of stroke

A national survey released today by The Ohio State University Wexner Medical Center shows that most women don't know the risks or symptoms females face when it comes to having a stroke.

28 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Studies reveal that dietary supplement can improve reproductive health

Current statistics on U.S. birth rates from the Centers for Disease Control and Prevention report a continued trend toward delayed motherhood. As fertility gradually declines in the 30s, particularly after age 35, the risk of experiencing difficulty conceiving may increase. In addition to age, there are other common reasons why women may experience difficulties conceiving, including: irregular ovulation cycles and poor egg quality, which may be associated with stress, lifestyle or poor diet.

13 Apr 2015

Contraception access: an interview with Pamela Weir, Chief Operating Officer, Medicines360

One of the key barriers for women to receiving highly effective and safe contraception is access, because of cost. With LILETTA™ women will have expanded access to an available IUD that is safe and effective when they need or want it...

From Medicines 360 7 Apr 2015

Contraception News and Research

Latest Contraception News and Research

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

Study compares costs of immediate birth control implant insertion with costs of unintended pregnancy

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

New tool kit aims to support family planning efforts

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Penn study highlights need for more guidance on contraceptive use in women with cystic fibrosis

Mylan releases generic version of Seasonale Tablets in the U.S.

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

National survey shows that most women don't know risks or symptoms of stroke

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Alternative treatment options for uterine fibroids

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Studies reveal that dietary supplement can improve reproductive health

Contraception access: an interview with Pamela Weir, Chief Operating Officer, Medicines360

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Contraception News and Research

Latest Contraception News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in